Scienture Holdings, Inc. (NASDAQ:SCNX) Sees Large Decrease in Short Interest

Scienture Holdings, Inc. (NASDAQ:SCNX) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 105,863 shares, a decrease of 91.9% from the September 30th total of 1,304,235 shares. Currently, 7.4% of the shares of the stock are short sold. Based on an average daily volume of 699,440 shares, the days-to-cover ratio is currently 0.2 days.

Scienture Stock Up 1.7%

NASDAQ:SCNX traded up $0.05 during mid-day trading on Monday, reaching $2.93. The stock had a trading volume of 16,656 shares, compared to its average volume of 409,908. Scienture has a 1-year low of $2.64 and a 1-year high of $36.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.04 and a quick ratio of 2.97. The company has a market capitalization of $5.16 million, a price-to-earnings ratio of -0.06 and a beta of 3.34. The stock’s 50 day simple moving average is $7.00 and its two-hundred day simple moving average is $9.42.

Scienture (NASDAQ:SCNX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.25) by $2.18. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.96 million. Equities analysts anticipate that Scienture will post -5.75 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Scienture stock. Susquehanna International Group LLP acquired a new position in Scienture Holdings, Inc. (NASDAQ:SCNX) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned approximately 0.57% of Scienture at the end of the most recent reporting period. 5.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Maxim Group set a $6.00 price target on shares of Scienture and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a research note on Monday, September 21st. Finally, Zacks Research upgraded shares of Scienture to a “hold” rating in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

Scienture Company Profile

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its areas of interest include neurological and psychiatric conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain.

The company’s portfolio includes prescription pharmaceutical products and product candidates intended to provide alternative delivery methods or other potential benefits compared with existing treatments.